RecruitingPhase 4NCT07633470

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease

Sponsor

Alpha Cognition, Inc

Enrollment

150 participants

Start Date

May 20, 2026

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Zunveyl® for people with alzheimer disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.